Endonovo Therapeutics, Inc. income statement ENDV

Annual Quarterly

In fiscal 2022, which ended Dec 31, 2022, Endonovo Therapeutics, Inc. reported revenue of $135,355, up 85.2% from the year before. It recorded a net loss of $18.5 million. The operating loss came to $3.3 million, an operating margin of -2411.7%. Over the twelve months ended Sep 30, 2023, revenue was $255,723 and the net loss was $4.4 million. Across the 8 fiscal years shown, revenue grew from $30,581 in fiscal 2012 to $135,355 in fiscal 2022, about 23.7% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2023 Sep 30, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016	FY 2015 Dec 31, 2015	FY 2014 Dec 31, 2014	FY 2012 Dec 31, 2012
Revenue	0 +1699.9%	0 +85.2%	0 -55.9%	0 -46.5%	0 +272.5%	0	—	—	0 -82.4%	0	0 -32.9%
Cost of revenue	0 -30.7%	0 -33.3%	0 -77.1%	0 -30.0%	0 +622.2%	0	—	—	0 -86.0%	0	—
Gross profit	0 +110229.1%	0 +115.7%	0 -42.1%	0 -53.7%	0 +208.2%	0	—	—	0 -75.8%	0	—
Research and development	—	—	0 -100.0%	0 -97.9%	0 -44.2%	0 +138.2%	0	—	—	—	—
Operating income	-3 +17.1%	-3 -46.6%	-2 +23.5%	-3 +23.5%	-4 +8.4%	-4 +9.7%	-5 +14.9%	-5 -111.0%	-3 -17.0%	-2	-2 -1724.0%
Other income (expense)	-2 -20617.6%	-15 -1631.7%	-1 -134.9%	3	—	—	—	—	—	—	—
Pretax income	-4 -40.0%	-18 -495.0%	-3 -684.9%	-0 +97.7%	-17 -169.0%	-6 +40.5%	-11 -103.4%	-5 +21.4%	-7 -605.1%	-1	-2 -1952.3%
Income tax	—	—	—	—	—	—	—	—	0 -100.0%	—	0 -100.0%
Net income	-4 -40.0%	-18 -495.0%	-3 -684.9%	-0 +97.7%	-17 -169.0%	-6 +40.5%	-11 -103.4%	-5 +21.4%	-7 -605.1%	-1	-2 -1934.9%
Basic EPS	-0.02	-0.13	—	—	—	—	—	—	—	—	—
Weighted average shares, basic	254	139	—	—	—	—	—	—	—	—	48 +961.5%
Other measures
Depreciation and amortization	1 +0.0%	1 -0.2%	1 -0.4%	1 +0.1%	1 +0.0%	1 +4305.0%	0 -6.8%	0 +7.2%	0 -6.1%	0	0 +3682.8%
EBITDA	-2 +21.5%	-3 -65.9%	-2 +30.2%	-2 +28.4%	-3 +10.0%	-4 +23.5%	-5 +14.9%	-5 -111.6%	-3 -17.2%	-2	-2 -1703.7%
Interest coverage	—	—	-2.36x	—	—	—	—	—	—	—	—
Margins
Gross margin	96.21%	92.62%	79.50%	60.57%	69.89%	84.47%	—	—	49.31%	35.99%	—
Operating margin	-1,023.16%	-2,411.69%	-3,045.68%	-1,756.49%	-1,228.08%	-4,995.33%	—	—	-60,132.73%	-9,057.59%	-5,697.49%
Pretax margin	-1,722.23%	-13,649.17%	-4,247.17%	-238.60%	-5,582.37%	-7,729.53%	—	—	-158,633.90%	-3,966.16%	-6,260.59%
Profit margin	-1,722.23%	-13,649.17%	-4,247.17%	-238.60%	-5,582.37%	-7,729.53%	—	—	-158,633.90%	-3,966.16%	-6,260.59%
EBITDA margin	-770.18%	-1,933.75%	-2,158.61%	-1,363.69%	-1,018.42%	-4,214.41%	—	—	-59,786.35%	-8,992.54%	-5,576.39%

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Electromedical & Electrotherapeutic Apparatus (SIC 3845)
Listed as: ENDV (OTC)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Woodland Hills, CA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1528172
Former names: Hanover Portfolio Acquisitions, Inc. (until Jan 24, 2014)

Other Electromedical & Electrotherapeutic Apparatus companies

All 31 Electromedical & Electrotherapeutic Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.